Back

Effectiveness and safety of rivaroxaban vs apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Adjuvant strategies to peripheral artery disease Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Loubna Dari

University Hospital of Bordeaux, Bordeaux (France)

6 More presentations in this session

Presentation thumbnail
GLP-1 RA vs DPP4i in patients with prior major adverse limb evets
Ms C. Chen (Tao-Yuan, TW)
Abstract Slides Video
Presentation thumbnail
Association of baseline and longitudinal changes in non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in peripheral artery disease
Doctor Z. Liu (Sha Tin, HK)
Abstract Slides Video
Presentation thumbnail
Contemporary treatment patterns and outcomes of endovascular therapy in octogenarians and older with peripheral artery disease: a multicentric analysis of 1980 patients from the RECCORD registry
Doctor D. Pinsdorf (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Serum ferritin level could predict wound healing in chronic limb-threatening ischemia patients after endovascular therapy
Doctor J. Nakamura (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Effect of behaviour change interventions on walking capacity, clinical outcomes, and quality of life in intermittent claudication: insights from the OPTIMA systematic review and meta-analysis
Doctor U. Abaraogu (Enugu, NG)
Abstract Slides Video

Access the full session

Session thumbnail
Adjuvant strategies to peripheral artery disease

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Session
Cardiovascular treatment: protecting the brain and the limbs
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources